目的这是由德国妇产科学会(DGGG)和奥地利妇产科学会(OEGGG)发布和协调的官方指南。由于它们的稀有和异质性组织病理学,子宫肉瘤在如何进行临床治疗方面具有挑战性,治疗需要多学科的方法。据我们所知,目前,对于这种异质性肿瘤组的适当治疗,尚无有约束力的循证建议.方法该S2k指南于2015年首次发布。此处发布的更新是一个具有代表性的跨学科专家组达成共识的结果,他们在DGGG指南计划的背景下对子宫肉瘤的文献进行了系统的搜索,OEGGG和SGGG。参与的专业协会成员在经过适度的结构化共识过程后达成了正式共识。建议基于共识的建议和声明包括流行病学,分类,分期,症状,子宫肉瘤的一般诊断检查和一般病理学以及发展子宫肉瘤的遗传易感性。还包括关于平滑肌肉瘤管理的声明,(低度和高度)子宫内膜间质肉瘤和未分化子宫肉瘤和腺肉瘤。最后,该指南考虑了子宫肉瘤的随访和碎裂以及向患者提供的信息.
Aims This is an official
guideline published and coordinated by the German Society of Gynecology and Obstetrics (DGGG) and the Austrian Society of Gynecology and Obstetrics (OEGGG). Because of their rarity and heterogeneous histopathology, uterine sarcomas are challenging in terms of how they should be managed clinically, and treatment requires a multidisciplinary approach. To our knowledge, there are currently no binding evidence-based recommendations for the appropriate management of this heterogeneous group of tumors. Methods This S2k
guideline was first published in 2015. The update published here is the result of the consensus of a representative interdisciplinary group of experts who carried out a systematic search of the literature on uterine sarcomas in the context of the
guidelines program of the DGGG, OEGGG and SGGG. Members of the participating professional societies achieved a formal consensus after a moderated structured
consensus process. Recommendations The consensus-based recommendations and statements include the epidemiology, classification, staging, symptoms, general diagnostic work-up and general pathology of uterine sarcomas as well as the genetic predisposition to develop uterine sarcomas. Also included are statements on the management of leiomyosarcomas, (low and high-grade) endometrial stromal sarcomas and undifferentiated uterine sarcomas and adenosarcomas. Finally, the
guideline considers the follow-up and morcellation of uterine sarcomas and the information provided to patients.